Springer Nature account plan
Publishing academic knowledge
At a glance
Springer Nature, the Berlin research, health and education publisher of Nature and over 3,000 journals: €1,926.4m 2025 revenue, around 9,500 staff.
Springer Nature publishes research journals and books (including Nature, Scientific Reports and BMC), health information for medical professionals and Macmillan Education learning materials. Its customers are academic, government and corporate libraries, research funders and authors, pharmaceutical companies, healthcare professionals, schools and governments, and more than 53% of its primary research is published open access. 2025 revenue was €1,926.4m with underlying growth of 6.2%, adjusted operating profit (AOP) €543.6m and a net result of €356.0m. It has around 9,500 employees in more than 40 countries. A KGaA registered in Berlin and listed in Frankfurt since October 2024, it is controlled through its General Partner by Holtzbrinck and funds advised by BC Partners; Frank Vrancken Peeters is CEO.
Business units
Research
€1,517.2m, 79% of 2025 group revenueJournals (more than 3,000, including 66 Nature-branded titles and more than 770 full OA journals), Springer and Palgrave Macmillan books, and services such as data, text and data mining, careers and conferences, sold to libraries, funders and authors. It generated 89% of 2025 AOP and grew 7.2% underlying in H1 2026 to €748.0m, led by open access and transformative agreements.
Health
€191.0m, 10% of 2025 group revenueSpringer Medizin, BSL, Healthcare and Cureus provide specialist information, education and events to healthcare professionals, mainly in German-speaking regions and the Netherlands, plus scientific writing services for pharmaceutical companies. H1 2026 revenue was €89.9m, up 1.3% underlying, as weak pharma marketing spend held back growth.
Education
€219.8m, 11% of 2025 group revenueMacmillan Education sells English Language Teaching (Spain, Mexico, Poland, Brazil) and K-12 curriculum resources (India, Mexico, South Africa), with 3.2 million active users on Macmillan Education Everywhere. H1 2026 revenue was €102.8m, up 3.5% underlying, while the AOP margin fell to 2.2%.
Strategic priorities
- Drive the transition to open access
- Open access is called the main driver of growth; 19 new transformative agreements in H1 2026 took the total to more than 100, covering more than 4,400 institutions, with the US the main remaining opportunity.
- Technology and AI in publishing
- Over 60% of submissions ran through the SNAPP platform in 2026, nearly 60 AI assists are implemented, and the company plans investment in agentic AI while keeping a human in the loop.
- New AI revenue
- Nature Research Assistant had about 25,000 beta users with a commercial launch planned for early 2027, and ARC3 licenses AI-ready content as an extension of text and data mining.
- Margin expansion
- The company is committed to grow AOP ahead of revenue and is on track to reach its mid-term target of 100bps margin improvement one year early.
- Research integrity
- 75 dedicated staff and about 20 AI checks per paper screen for image manipulation, fake references, fabricated text and paper-mill patterns.
- Portfolio focus
- Consumer Media (Scientific American and Spektrum) was sold in 2026; capital goes to organic growth, value-accretive M&A in portfolio expansion and AI, and a progressive dividend.
Latest results
In H1 2026 revenue was €939.8m, up 1.5% reported and 6.2% underlying, and AOP rose to €246.2m (+7.7% underlying) with a group AOP margin of 26.2%. Research led with underlying revenue growth of 7.2%, article publication growth of 13% and submissions up 30%, while Health grew 1.3% and Education 3.5% underlying. The net result fell to €101.3m from €129.2m on a weaker financial result. Free cash flow rose to €267.6m and leverage fell to 1.6x. Guidance was raised to underlying revenue growth of around 6% in 2026 and an underlying AOP margin increase of at least 30 basis points.
Investments and deals
- Content and platform investment
- Investment in intangible assets, property and content was €146.6m in 2025, including €45.7m on eBooks and databases in Research and €23.2m on Education content; technology and talent investment totals €188 million since 2021.
- New journals
- 50 new journals were launched in 2025 and 39 in H1 2026, with Nature Books launched in July 2026.
- Refinancing
- €500.0m of promissory loan notes were issued in November 2025 to partly repay term loan B, cutting 2025 interest expenses to €104.5m from €156.4m.
- Consumer Media divestment
- Scientific American was sold in June 2026 and Spektrum der Wissenschaft closed in July 2026, described as not a core area of strategic focus.
- Shareholder returns
- A €0.83 per share dividend (€165.1m) was paid in 2026 and a five-year buyback authorisation was proposed for excess capital.
Challenges and risks
- Public funding and US policy
- Research and education budgets face fiscal pressure; the US is about 25% of revenue and 12% of articles, and NIH proposals to cap APC contributions are a stated risk.
- AI disruption and misuse
- New entrants or changed researcher behaviour could disrupt publishing, bad actors use AI to abuse it, and AI-related copyright litigation is a regulatory risk.
- Scaling peer review
- Submissions grew 30% in H1 2026, making it harder to find enough editors and reviewers and to hold turnaround times.
- Weak pharma and education markets
- Pharma marketing spend cuts hit Health's scientific writing services, and Education faced funding constraints and postponed curricula in South Africa and currency effects in Argentina and India.
- Currency
- A weaker US dollar weighed on 2025 reported figures, and the FX headwind was around 33bps on the H1 2026 margin.
What leadership says
“At the moment, we don't see a slowdown.”
“Europe is essentially fully covered by TA's”
“I don't think it's being cautious. I think it's just being realistic.”
“truly committed to grow our AOP ahead of revenue”
Where a supplier can help
- Editorial workflow automation
- Tied to the scaling peer review challenge and the AI priority: reviewer-finding, screening and production automation help absorb 30% submission growth without longer turnaround times.
- Research integrity tooling
- Tied to the research integrity priority: image forensics, reference checks and paper-mill detection extend the about 20 AI checks run on each paper.
- AI content licensing infrastructure
- Tied to the new AI revenue priority: attribution, provenance and secure delivery infrastructure support ARC3 and agreements such as OpenEvidence.
- Institutional sales in the US
- Tied to the open access priority: account intelligence and contract tooling help convert US libraries to transformative agreements, where around half of 40 active discussions sit.
- Corporate research customers
- Tied to the text and data mining growth in Research: corporates fund two thirds of global R&D but are less than a fifth of Research revenue, an opening for corporate go-to-market partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Springer Nature?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Springer Nature Annual Report 2025
- Springer Nature is a Berlin-based research, health and education publisher (Nature Portfolio, Springer, BMC, Palgrave Macmillan, Macmillan Education, Springer Medizin), listed on the Frankfurt Stock Exchange since October 2024, with around 9,500 employees in more than 40 countries and 102 fully consolidated entities.
- FY2025 revenue was €1,926.4m (2024: €1,847.1m), underlying growth 6.2%; adjusted operating profit (AOP) €543.6m (2024: €512.4m), underlying growth 9.2%; net result €356.0m (2024: €69.0m); basic adjusted EPS €1.93 (2024: €1.09).
- Research is the engine: €1,517.2m revenue (+7.4% underlying) and €486.4m AOP (+9.9%); Health €191.0m (+2.7%); Education €219.8m (+0.8%).
- Open access (OA) is the dominant publishing model and main growth driver: more than 53% of 539,000 primary research articles were published OA; 85 transformative agreements (TAs) at year end, 19 new in 2025 (incl. Big Ten Academic Alliance in the US and a first national TA in Malaysia).
- Technology and AI are a strategic pillar: more than half the portfolio runs on the proprietary Snapp article platform; Nature Research Assistant in beta with 20k+ users; €188m invested in technology and talent since 2021; 75 people dedicated to research integrity.
- 3.1 million manuscripts submitted in 2025, a significant increase; 5.6bn content downloads across platforms.
- Free cash flow rose to €297.8m (2024: €218.7m); financial leverage fell to 1.7x (2024: 2.3x); €500m promissory loan notes issued in November 2025 to refinance senior loans; proposed dividend €0.83 per share (€165.1m).
- 2026 guidance: underlying revenue growth of 5% to 6% and an improvement in underlying AOP margin of around 30bps.
- Top risks: public research and education budgets (e.g. NIH proposals to cap APC funding), AI disruption and AI-related copyright litigation, research integrity (paper mills), cyber security, FX (mainly US dollar).
- Springer Nature 2026 Half-Year Financial Report
- H1 2026 revenue €939.8m (H1 2025: €925.9m), underlying growth 6.2%; reported growth only 1.5% because of currency (stronger euro vs. Indian rupee, Argentine hyperinflation).
- Adjusted operating profit €246.2m (H1 2025: €240.6m), underlying +7.7%; group AOP margin 26.2% (26.0%).
- Research drove growth: revenue €748.0m (+7.2% underlying), AOP €228.7m (+8.2%), margin 30.6%; 19 new transformative agreements and 39 new journals in the half.
- Health €89.9m revenue (+1.3%), hit by weaker scientific writing services as pharma marketing budgets tightened; Education €102.8m (+3.5%), led by K-12 Curriculum in Southern Africa and India.
- Consumer Media sold: Scientific American (US, closed June 2026) and Spektrum der Wissenschaft (Germany, closed July 2026).
- Free cash flow €267.6m (H1 2025: €203.8m); leverage down to 1.6x; dividend of €165.1m paid.
- Adjusted EPS fell to €0.71 (€0.83) on a normalised financial result and higher tax.
- 2026 guidance raised: underlying revenue growth of around 6% (was 5% to 6%) and underlying AOP margin up at least 30 basis points.
- Springer Nature H1 2026 results conference call transcript
- CEO Frank Vrancken Peeters and CFO Alexandra Dambeck presented H1 2026 on 5 August 2026: revenue up 6% underlying, AOP up 8%, guidance raised to around 6% growth with at least 30bps margin improvement.
- Research is almost 80% of group revenue and more than 90% of AOP; around 60% of Research revenue is contracted for three to five years; the 2026 renewal season closed with an almost 100% retention rate.
- Article publications grew 13% against a market estimated at around 8%; submissions grew 30%, with no slowdown seen and growth picking up in North America and Western Europe.
- AI: over 60% of submissions now go through the SNAPP platform; Nature Research Assistant has about 25,000 beta users with CSAT above 80% and a commercial launch planned for early 2027 (B2B add-on plus a consumer model).
- ARC3, the AI content-licensing offer (subscription, attribution, provenance), signed OpenEvidence; there is a pipeline but little 2026 revenue impact expected.
- US policy: the US is about 25% of revenue and 12% of articles, about half federally funded (about 6% of articles); management does not expect the OMB proposals to hurt 2026 results.
- Consumer Media (Scientific American, Spektrum) sold to sharpen the Research focus; capital priorities are organic growth, balance sheet, value-accretive M&A, progressive dividend, then possible buybacks.
- CFO Alexandra Dambeck leaves at the end of September 2026; a successor was expected to be named within two to three weeks.
- Springer Nature FY 2025 results conference call transcript
- FY2025 results call (17 March 2026): revenue up 6% underlying and AOP up 9%; free cash flow €298m; leverage in the lower half of the 1.5x-2.0x target range; dividend 83 cents, a yield above 5%.
- Research is almost 80% of revenue and almost 90% of AOP; global article market grew about 8% in 2025 while Springer Nature's output grew a little more than 12%; full OA grew around twice the market's ~12%; submissions up more than 30%.
- 85 transformative agreements cover over 4,000 institutions; 40 active discussions on new deals, around half in the US.
- AI strategy has three strands: transform publishing, disseminate knowledge, maintain trust; nearly 60 AI assists live and more than 50 more under evaluation; SNAPP used by more than 50% of journals.
- ARC3 licenses content for AI via an MCP server on an inference/RAG model, not for training; corporates are two thirds of global R&D spend but less than a fifth of Research revenue.
- US exposure: about a quarter of revenue and 12% of articles; about 4% of total articles NIH-funded; average APC just over €2,000.
- 2026 guidance: 5% to 6% underlying revenue growth, about 30bps margin improvement; mid-term 100bps margin target reached one year early; a five-year buyback authorisation proposed.
- Mid-term tax rate guided at 32% to 34% (rather 34%), with a possible 400bps reduction from interest-deduction projects.
Questions about Springer Nature
What does Springer Nature do?
Springer Nature publishes research journals and books, including Nature and Scientific Reports, provides information and education for healthcare professionals, and sells Macmillan Education learning materials.
What is Springer Nature's revenue?
2025 revenue was €1,926.4m with 6.2% underlying growth and AOP of €543.6m. H1 2026 revenue was €939.8m.
How many employees does Springer Nature have?
Around 9,500 employees (9,424 FTEs) in more than 40 countries at 31 December 2025.
What is Springer Nature's strategy?
Four priorities: driving the transition to open access, harnessing technology and AI alongside domain expertise, being a place where skilled colleagues thrive, and enhancing business performance while growing responsibly.
Who leads Springer Nature?
Frank Vrancken Peeters is Chair of the Management Board and CEO; Dr Stefan von Holtzbrinck chairs the Supervisory Board. CFO Alexandra Dambeck was due to leave at the end of September 2026.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)